Cancer Genomics Research Paper

Content type

User Generated

Subject

Health & Medical

Type

Research Paper

Uploaded By

Yqvznhy

Pages

Rating

[Report on Cancer Genomics]

Insert Your Name

Institution Name, Location

Department

University

Presented to

Instructor’s Name, Course

Cancer Genomics

Molecular Basis

Cancer is uniquely known for its genomic instability especially the stepwise build-up

of mutations within its main oncogenes. ErbB2 or HER2 which is a receptor tyrosine-kinase

belonging to the epidermal-growth-factor receptor family has caught the devotion of cancer

researchers since it is one of the oncogene which alters NIH3T3-cells (1). In breast cancer,

HER2 has been observed to be creating abnormal signalling as it phosphorylate in several

breast tumours (28). The trans-modulation takes place through EGFR signalling even without

ligands whereby ErbB2 operates as a signalling subcomponent of three other more receptors

(1). Notably, in breast cancer, ErbB2 has other key partners known as ErbB1 and ErbB3

which are kinase malfunctioning receptors and whose intoxicating mitogenic acts are

triggered in hetero-dimeric complexes (28). These heterodimers seems to dodge typical

inactivation procedures by reducing the degree of ligand detachment by subsequently

internalizing though rather sluggishly. Consequently, they evade the degradative conduit by

appearing on the surface of the cell and thereby powerfully recruiting subsistence and

mitogenic conduits like the mitogen triggered protein-kinases or in some instances

phosphatidylinositol-3-kinase (1). Therefore, the hyper-activated motioning via ErbB2

signalling system leads to dys-regulation of cell-sequence homeostatic mechanism, including

the up-regulation of vigorous cyclin-D/CDK multiplexes (28). It has been found that D-type

cyclins in conjunction with CDK inhibitor known as p21waf1 are crucial in the evasion

process from apoptosis (1).

This molecular understanding of breast cancer is a good example of an understanding

of cancer cell lines can result in the development of a therapy. The observation is that any

drug should belong to the tyrosine-kinase inhibitors class of medications as they specifically

target tyrosine kinases (1). Herceptin which is essentially an antibody that seeks out cells that

have a high amount of HER2 was developed based on the observation that monoclonal

antibodies can hinder growth of tumour in cancer development. Since ErbB2 possesses no

ligand, HER2 antibody can be able to target ErbB2 and thus suppress signals receptor

dimerization (1). Herceptin protein has been found to overexpress in breast cancers in the

range of 15 to 30 percentages and this is attributed to its gene amplification (28). Herceptin is

usually administered in IV and for that reason it is humanized so as to halt the antibody from

being identified by the immune-system (1). Notably, Herceptin only acts as a treatment not a

cure since the cancer reappears later as most of the transformations involved are protein to

End of Preview - Want to read all 12 pages?

Access Now

Unformatted Attachment Preview

1 [Report on Cancer Genomics] By Insert Your Name Institution Name, Location Department University Presented to Instructor’s Name, Course 2 Cancer Genomics Molecular Basis Cancer is uniquely known for its genomic instability especially the stepwise build-up of mutations within its main oncogenes. ErbB2 or HER2 which is a receptor tyrosine-kinase belonging to the epidermal-growth-factor receptor family has caught the devotion of cancer researchers since it is one of the oncogene which alters NIH3T3-cells (1). In breast cancer, HER2 has been observed to be creating abnormal signalling as it phosphorylate in several breast tumours (28). The trans-modulation takes place through EGFR signalling even without ligands whereby ErbB2 operates as a signalling subcomponent of three other more receptors (1). Notably, in breast cancer, ErbB2 has other key partners known as ErbB1 and ErbB3 which are kinase malfunctioning receptors and whose intoxicating mitogenic acts are triggered in hetero-dimeric complexes (28). These heterodimers seems to dodge typical inactivation procedures by reducing the degree of ligand detachment by subsequently internalizing though rather sluggishly. Consequently, they evade the degradative conduit by appearing on the surface of the cell and thereby powerfully recruiting subsistence and mitogenic conduits like the mitogen triggered protein-kinases or in some instances phosphatidylinositol-3-kinase (1). Therefore, the hyper-activated motioning via ErbB2 s ...
Purchase document to see full attachment

Tags: cancer Cancer Genomics Molecular basis DNA Sequencing Technologies Cancer Heterogeneity